Editas Medicine Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Editas Medicine stock has a consensus rating of "Buy" and an average price target of $5.78. The average 1-year stock price forecast is 144.92% higher than the current stock price, while the lowest is $1.00 (-57.63%) and the highest is $15 (+535.59%).

Price Target: $5.78 (+144.92%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.00	$5.78	$5.00	$15
Change	-57.63%	+144.92%	+111.86%	+535.59%

Analyst Ratings

The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	6	6	6	7	7	7
Buy	0	0	0	0	0	0
Hold	7	6	6	5	5	4
Sell	2	2	2	2	2	2
Strong Sell	0	0	0	0	0	0
Total	15	14	14	14	14	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Miller Evercore ISI	Evercore ISI	Buy Maintains $15	Buy	Maintains	$15	+535.59%	May 27, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $5	Buy	Reiterates	$5	+111.86%	May 26, 2026
Boris Peaker JonesTrading	JonesTrading	Buy Maintains $13 → $8	Buy	Maintains	$13 → $8	+238.98%	May 14, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Sell Maintains n/a	Sell	Maintains	n/a	n/a	May 7, 2026
Luca Issi RBC Capital	RBC Capital	Hold Maintains $4	Hold	Maintains	$4	+69.49%	May 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

14.35M

from 40.52M

-64.58%

from 40.52M

Revenue Next Year

14.68M

from 14.35M

2.30%

from 14.35M

EPS This Year

-1.00

from -1.80

EPS Next Year

-0.94

from -1.00

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	25.54M	19.71M	78.12M	32.31M	40.52M	14.35M
Revenue Growth	-71.85%	-22.83%	296.32%	-58.64%	25.40%	-64.58%
Gross Profit	-116.96M	-155.25M	-99.53M	-166.93M	-49.43M	12.20M
Gross Margin	-457.89%	-787.57%	-127.40%	-516.60%	-122.00%	85.00%
Operating Income	-193.15M	-225.95M	-169.18M	-238.92M	-99.34M	-112.00M
Net Income	-192.50M	-220.43M	-153.22M	-237.09M	-160.06M	-113.89M
EPS	-	-	-	-	-1.80	-1.00
Free Cash Flow	-85.55M	-102.27M	-87.81M	-122.46M	-71.48M	-115.50M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	32.4M
Avg	14.4M
Low	5.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-20.0%
Avg	-64.6%
Low	-85.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.00
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-